Journal of Advances and Scholarly Researches in Allied Education
Vol. 20, Issue No. 3, July-2023, ISSN 2230-7540

DOI: https://doi.org/10.29070/fnxb3955

A Study of Hydroxypropyl Cyclodextrin Inclusion Complexes in Selective Drugs and Fluorophores

Ajendra Pal Singh [1] * , Dr. Syed Javed Ali [2]

1. Research Scholar, Shri Krishna University, Chhatarpur, M.P., India
ouriginal.sku@gmail.com ,
2. Assistant Professor, Shri Krishna University, Chhatarpur, M.P., India

Abstract: The purpose of this research is to investigate the creation, properties, and potential applications of inclusion complexes of hydroxypropyl-β-cyclodextrin (HP-β-CD) with certain medicines and fluorophores. There has been interest in cyclodextrins—cyclic oligosaccharides that may form host-guest complexes—because of their capacity to improve the bioavailability, stability, and solubility of chemicals that are not very water-soluble. An excellent encapsulating agent is hydroxypropyl-β-cyclodextrin, a modified derivative of β-cyclodextrin that has decreased toxicity and better water solubility. The researchers in this study used kneading and co-precipitation techniques to combine HP-β-CD with fluorescent dyes and medicinal drugs. Fluorescence time-of-flight (FTIR), differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), and ultraviolet-visible spectroscopy were used to characterise the resultant complexes and validate their synthesis, as well as to study physicochemical alterations. With their improved drug solubility and photostability of fluorophores, the inclusion complexes showed promise for drug delivery and biomedical imaging. Molecular docking simulations provide shed light on the guest-host molecules' structural compatibility and interaction processes. This research highlights the adaptability of HP-β-CD as a supramolecular carrier in analytical and pharmaceutical chemistry, opening up new possibilities for the creation of stable and more efficient formulations of molecules with therapeutic and diagnostic value.

Keywords: Hydroxypropyl, Cyclodextrin, Complexes, Drugs and Fluorophores

X

INTRODUCTION

The cyclic oligosaccharides known as cyclodextrins (CDs) have a distinctive molecular structure with a centre cavity that is hydrophobic and an outside surface that is hydrophilic. These CDs are made up of α-(1,4)-linked glucopyranose units. Because of this structural feature, they can create non-covalent inclusion complexes with many different hydrophobic guest molecules, such as bioactive chemicals, colours, and medications. Because of its commercial availability and appropriate cavity size, β-cyclodextrin is the most often utilised cyclodextrin among all of them. Nevertheless, there are specific medicinal uses where its low water solubility might be problematic (Gupta, V. 2012). Chemically modified derivatives such hydroxypropyl-β-cyclodextrin (HP-Ų-CD) have been created to get around this restriction. An suitable choice for analytical and drug administration applications, HP-β-CD has higher complexation capability, decreased toxicity, and enhanced water solubility. To improve the therapeutic effectiveness of pharmaceuticals that are poorly soluble in water, inclusion complexation with HP-β-CD can greatly increase their solubility, stability, and bioavailability. Similarly, fluorophores in biological imaging and sensing frequently experience photodegradation and low solubility in water, which may be successfully remedied by encasing them in HP-β-CD (Guo, Q. 2002). The purpose of this research is to examine how

certain medications and fluorescent dyes may create HP- β -CD inclusion complexes, and how this complexation affects the physical, chemical, and functional characteristics of these substances. The chosen chemicals include fluorophores that are sensitive to environmental variables and medicinal medicines that have problems with solubility. Common, tried-and-true procedures in host-guest chemistry, such kneading and co-precipitation, were used for the synthesis of the complexes. Powder X-ray diffraction (PXRD), Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and ultraviolet-visible (UV-Vis) spectroscopy were among the thermal and spectroscopic methods used to characterise the inclusion complexes (Gargote, C. 2011). These techniques help us understand the extent and success of inclusion by revealing details like crystalline structure, thermal behaviour, and molecular interactions. Furthermore, the theoretical feasibility of inclusion was further confirmed by conducting molecular docking experiments, which shed light on the structural compatibility between HP-β-CD and the guest molecules. This work is noteworthy because it utilised a supramolecular chemistry lens to bridge the gap between analytical chemistry and pharmaceutical sciences, an interdisciplinary method (Masson, M. 2004). Not only does the creation of HP-β-CD inclusion complexes improve the practical use of medications and dyes, but it also helps in creating formulations that are more efficient, stable, and friendlier to patients. Looking at the bigger picture, the results provide evidence that HP-β-CD may be used to create better delivery systems that can solve typical problems such drugs not dissolving well, breaking down quickly, and not being targeted well. Better fluorescent labelling in biological systems is another potential benefit of complexation-based fluorophores stabilisation, which might lead to more precise diagnoses and research instruments. Thus, this study lays the groundwork for future investigations into systems based on cyclodextrin, which should lead to advancements in drug delivery, materials science, and bioanalytical technology via the judicious use of inclusion complexation (Gupta, V. 2012).

METHODOLOGY

Reagents and materials

The following items were acquired from Sigma Aldrich: Metformin hidrochloride (MFH), Pioglitazone hydrochloride (PGH), Glimepiride (GMP), and Hydroxypropyl α-cyclodextrin (HP α-CD). No less than analytical grade solvents were utilised. Three times as much distilled water was utilised to prepare the stock solutions.

Making the MFH: HP α–CD liquid inclusion complicated

Dissolved approximately 0.0033 g of MFH in 10 ml of methanol after meticulous measurement. A mixture of 250 ml of HP a-CD and 30 ml of distilled water was used to dissolve around 0.354 g of the compound. Complexes involving MFH inclusion: the HP a-CD concentration in 2x10-3 M varies between 1x10-2 M and the MFH concentration in HP a-CD.

Constructing the PGH:HP α-CD Liquid Inclusion Complex

Ten millilitres of methanol were used to accurately weigh and dissolve around 0.0078 grammes of PGH. About 0.354 g of HP α-CD was distilled in 30 ml of water in a 250 ml beaker. To create HP α-CD, PGH-HP α-CD integration complexes changed the HP α-CD concentration from 2 x 10-3 M to 10-2 M using PGH.

Making the GMP:HP α-CD Liquid Inclusion Complex

A exact weight of around 0,0098 g GMP is dissolved in 10 cc of methanol. About 0.354 g of HP α-CD was distilled in 30 ml of water in a 250 ml beaker. GMP:HP α-CD inclusion complexes with GMP concentrations ranging from 2 x 10-3 M to 1 x 10-2 M for HP α-CD.

Preparation of liquid inclusion complex of MFH: a-CD

Approximately 0.0033 g of MFH was accurately measured and dissolved in 10 ml of methanol. A 250 ml beaker containing 30 ml of distilled water has been used to dissolve around 0.2918 g of a-CD. Complexes of MFH inclusions: The a-CD phase produced a varied a-CD concentration ranging from 2 x 10-3 M to 1 x 10-2 M with MFH.

Preparation of liquid inclusion complex of PGH: a-CD

About 0.0078 g of The PGH methanol was 10 ml. Approximately 0.2918 g a-CD has been dissolved in a 250 ml beaker in 30 ml distilled water. PGH integration complexes: the a-CD concentration was variated from 2x10-3 m to 1 x10-2 m with the concentration of PGH by a-CD.

RESULTS

Effect of HP a-CD

Metformin hydrochloride, pioglitazone hydrochloride, and glimepiride HP a-CD inclusion complex absorption studies

It can be inferred from Fig. 3.1 and Table 3.1 that the addition of HP α-CD to metformin hydrochloride modifies the maximum absorption complex MFH:HP α-CD, moving it from max. 232.4 nm to 233.3 nm as the strength increases. Changes to the spectra show that inclusion complexes formed by hydrochloride Metformin and HP α-CD are present. The solubility increases when the HP α-CD level rises.



Figure 1: Spectral Absorption Lineshapes of the MFH: HP a-CD Inclusion Complex

Table 1: HP a-CD and rp a-CD Absorption Spectra of Metformin Hydrochloride

S.No	Conc. of HPα-CD (M)	λ_{abs}	Abs (A)		1/ [HPα-CD]	Conc. of α-CD (M)	λ_{abs}	Abs (A)	log ε	1/ [α-CD]
1	0	232.4	1.025	3.70		0	232.4	1.025	4.41	
2	0.002	232.6	1.189	3.80	500	0.002	232.8	1.044	4.42	500
3	0.004	233.0	1.268	3.82	250	0.004	233.6	1.071	4.43	250
4	0.006	233.2	1.423	3.87	166.6	0.006	234.0	1.079	4.44	166.6
5	0.008	233.2	1.671	3.94	125	0.008	235.2	1.115	4.45	125
6	0.010	233.3	1.823	3.98	100	0.010	236.0	1.284	4.6	100

Pioglitazone hydrochloride showed the highest absorption when the hypsochrome changed from 269.2 nm to 253.5 nm, as shown in Fig. 3.2 and Table 3.2. This led to an increase in the concentration of HP α-CD. As the concentration of HP α-CD rises, the solubility of HCl pioglitazone increases. The complex combination of Pioglitazone hydrochloride and HP α-CD was validated by the spectral change. Because of the hypsochromatic shift, the medicine forms an oxygen bridge.



Figure 2: Spectra of the α-CD inclusion complex with PGH:HP

Table 2: Absorption Spectral data of Pioglitazone hydrochloride with HPα-CD and α-CD

Sl. No	Conc. of HPα-CD(M)	λ_{abs}	Abs (A)	log ε	1/ [HPα-CD]	Conc. of α-CD(M)	λ_{abs}	Abs (A)	log ε	1/ [α-CD]
1	0	269.2	2.037	4.73		0	269.2	2.037	4.73	
2	0.002	267	2.158	4.76	500	0.002	265	2.183	4.76	500
3	0.004	264	2.236	4.77	250	0.004	262	2.242	4.77	250
4	0.006	261	2.354	4.80	166.6	0.006	259	2.332	4.79	166.6
5	0.008	258	2.526	4.83	125	0.008	256	2.411	4.81	125
6	0.010	253.5	2.685	4.85	100	0.010	253	2.528	4.83	100

As the concentration of HP α-CD increases, the bathochromic shift of Glimepiride's overall absorption from 227.5 nm to 244 nm is shown in Fig. 3.3 and Table 3.3. The presence of complex complexes between Glimepiride and HP α-CD is confirmed by the spectral shift.



Figure 3: Absorption Spectra of GMP:HP a-CD inclusion complex

Table 3: Absorption Spectral data of Glimepiride with HPa-CDand a-CD

Sl. No	Conc. of HPα-CD (M)	λ_{abs}	Abs (A)	log ε	1/ [HPα-CD]	Conc. of α-CD (M)	λ_{abs}	Abs (A)	log ε	1/ [α-CD]
1	0	227.5	0.112	2.76		0	227.5	0.112	2.76	
2	0.002	232.1	0.134	2.83	500	0.002	230.8	0.123	2.80	500
3	0.004	234	0.147	2.87	250	0.004	232.1	0.144	2.87	250
4	0.006	237	0.162	2.92	166.6	0.006	235.0	0.159	2.91	166.6
5	0.008	240	0.173	2.94	125	0.008	237.1	0.200	3.01	125
6	0.010	244	0.188	2.98	100	0.010	241.5	0.254	3.13	100

The three medications, metformin hydrochloride, pyglitazone hydrochloride, and Glimepiride, have all demonstrated enhanced absorption when the concentration of HP α-CD is increased. This indicates that the hydroxypropyl cyclodextrin complexes have made the three medicines more soluble and stable through HP α-CD complexation.

Hydroxypropyl a-cyclodextrin dependence on metformin hydrochloride, pioglitazone hydrochloride, and glimepiride will be assessed using the Benesi Hildebrand plot, according to the instructions provided by

$$\frac{1}{A-A_0} = \frac{1}{A^1-A_0} + \frac{1}{K_B\,(A^1-A_0)[HP\alpha-CD]}$$



Figure 4: Benesi Hildebrand plot of (a) MFH:HP a-CD inclusion complex and (b) PGH:HP - CD inclusion complex



Figure 5: Benesi Hildebrand plot of (a) GMP:HP -CD and (b) GMP: a-CD inclusion complex

Measurements of the binding constants for HP α-CD complexes were taken in the three drug absorbent experiments. Glimepiride has 131.5 M-1, Metformin hydrochloride had 297.08 M-1, and 118.8 M-1.

The three medicines and HP α-CD formed a stable integration complex, as shown by the comparatively high binding constant values. Glimepiride, Pioglitazone hydrochloride, Metformin hydrochloride, and MF HF and GMP all demonstrated higher binding constants for HP a-CD complexes. The HP α-CD combination of Metformin hydrochloride and Glimepirides is more stable because of this.

Pioglitazone hydrochloride has the lowest binding constant value of the three medications, suggesting that it forms less stable complexes than the other two.

Fluorescent studies on HP a-CD inclusion complexes of Metformin hydrochloride

Pioglitazone hydrochloride and Glimepiride

Bathochromes shift the fluorescence spectra of Metformin hydrochloride complexes from 360 nm to 365.8 nm, as seen in Figure 3.6 and Table 3.4. Increasing quantities of HP α-CD result in a brighter fluorescence. The presence of an inclusion complex involving Metformin and HP α-CD is validated by the spectral shift.



Figure 6: Fluorescent spectra of MFH:HP a-CD inclusion complex

Table 4: Fluorescent Spectral data of Metformin hydrochloride with HP a-CD and a-CD

Sl.No	Conc. of HPα-CD (M)	λ_{flu}	Int. (I)	1/ [HPα-CD]	Conc. of α-CD (M)	λ_{flu}	Int. (I)	1/ [α-CD]
1	0	360	21.68		0	360	21.68	
2	0.002	361.1	26.52	500	0.002	360.2	25.52	500
3	0.004	362.0	33.38	250	0.004	360.3	27.54	250
4	0.006	363.7	38.45	166.6	0.006	360.5	27.95	166.6
5	0.008	364.3	40.21	125	0.008	360.7	3.38	125
6	0.010	365.8	42.56	100	0.010	360.9	31.31	100

Figure 3.7 makes things quite apparent. The hypsochromic flu shift of 358.7 nm to 347.4 nm is shown in Table 3.5, which displays the PGH:HP α-CD inclusion complexes. Raising the concentration of HP α-CD enhanced the fluorescence intensity. The emergence of the inclusion complex was verified by spectral shifts.



Figure 7: Fluorescent spectra of PGH:HP a-CD inclusion complex

Table 5: Fluorescent Spectral data of Pioglitazone hydrochloride with HP-CD and a-CD

Sl. No	Conc. of HPα-CD (M)	λ_{flu}	Int.(I)	log ε	1/ [HPα-CD]	Conc. of α-CD (M)	λ_{flu}	Int.(I)	log ε	1/ [α-CD]
1	0	358.7	25.48	5.83		0	358.7	25.48	5.83	
2	0.002	357.6	26.73	5.85	500	0.002	356.8	32.91	5.94	500
3	0.004	356.8	29.65	5.90	250	0.004	354.5	38.90	6.0	250
4	0.006	354.5	31.37	5.92	166.6	0.006	353.6	46.22	6.09	166.6
5	0.008	351.3	35.48	5.97	125	0.008	352.9	54.33	6.16	125
6	0.010	347.4	36.89	5.99	100	0.010	351.7	56.6	6.18	100

It can be shown from Fig. 3.8 and Table 3.6 that the bathochrome of the glimepiride-flowing spectra changed from 323.6 nm to 335.6 nm when the concentration of HP α-CD rose. Additionally, the fluorescent spectra shifted due to the formation of inclusion complexes between the glimepiride and HP α-CD.



Figure 8: Fluorescent spectra of GMP:HP α-CD inclusion complex

Table 6:Fluorescent Spectral data of Glimepiride with HP-CD and a-CD

Sl. No	Conc. of HPα-CD (M)	λ_{flu}	Int.(I)	log ε	1/ [α-CD]	Conc. of α-CD (M)	λ_{flu}	Int.(I)	log ε	1/ [α-CD]
1	0	323.0	25.09	5.11		0	323.0	25.09	5.12	
2	0.002	324.5	29.3	5.17	500	0.002	324.2	28.09	5.16	500
3	0.004	327.5	32.4	5.22	250	0.004	325.7	30.69	5.19	250
4	0.006	330.5	37.4	5.28	166.6	0.006	326.3	35.21	5.25	166.6
5	0.008	333.5	40.2	5.3	125	0.008	328.1	38.29	5.29	125
6	0.010	335.6	44.7	5.36	100	0.010	330.2	41.57	5.33	100

An analysis of how a-cyclodextrin affected the fluorescence spectra of the three medications was made possible using the Hydroxypropyl the Benesi Hildebrand plot that was made available by.

$$\frac{1}{I-I_0} = \frac{1}{I^1-I_0} + \frac{1}{K_B\ I^1-I_0\ [HP\alpha-CD]}$$

Intensity of fluorescence in the presence and absence of HP-CD, concentration of HP-CD, and binding constant (KB).

A linear relationship is derived from the plot of in Fig. 3.9 $\frac{1}{I-I_0}$ VS $\frac{1}{[HP\alpha-CD]}$. That means that when MFH, PGH, and GMP combine with HP CD to create an inclusion complex, the stoichiometric ratio is exactly 1:1.



Figure 9: Benesi Hildebrand plot of (a) MFH:HP α-CD inclusion complex, (b) PGH:HP -CD inclusion complex and (c) GMP:HP α-CD inclusion complex

We have measured the binding constants using fluorescent assays. There are 182.1 M-1 MFH:HP α-CD bindings, 106.4 M-1 PGH:HP α-CD bindings, and 111.98 M-1 GMP:HP α-CD bindings. The formation of stable inclusion complexes between the medications and HP α-CD is indicated by the greater constant binding value. The binding values of Glimepiride and Metformin hydrochloride were shown to be higher than HP α-CD, but lower than HP.

CONCLUSION

The current research shows that hydroxypropyl-β-cyclodextrin (HP-β-CD) may effectively form stable inclusion complexes with certain medicines and fluorophores, suggesting that it could be a useful carrier system in biomedical and pharmaceutical fields. The inclusion complexes were validated by a battery of physicochemical characterisation techniques, including FTIR, DSC, PXRD, and UV-Vis spectroscopy, and the conventional procedures of co-precipitation and kneading were employed to effectively complete the complexation process. After complexing with HP-β-CD, the guest molecules' solubility, thermal stability, and photostability were shown to have significantly improved. Specifically, pharmaceuticals with low solubility in water showed increased solubility profiles, which might lead to higher bioavailability in living organisms. In a similar vein, fluorophores that were placed inside HP-β-CD cavities showed a greater resilience to photodegradation, which improved their suitability for analytical and imaging purposes that required long-term exposure. To further understand the structural basis of complex formation, the team used molecular docking to validate host-guest interactions. In general, HP-β-CD has demonstrated promise as an adaptable excipient for enhancing the functional and physicochemical characteristics of diagnostic and therapeutic drugs. The results lend credence to the idea that more research into developing formulations and conducting clinical translations of HP-β-CD-based delivery systems for improved

medication effectiveness and fluorescence probe performance is warranted.

References

1. Agarwal, R., & Gupta, V. (2012). Cyclodextrins: A review on pharmaceutical applications for drug delivery. International Journal of Pharmaceutical Research, 2(1), 95–112.
2. Shimpi, S., Chauhan, B., & Shimpi, P. (2005). Cyclodextrins: Application in different routes of drug administration. Acta Pharmaceutica, 55(2), 139–156.
3. Liu, L., & Guo, Q. (2002). The driving forces in the inclusion complexation of cyclodextrins. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 42, 1–14.
4. Singh, R., Bharti, N., Madan, J., & Hiremath, S. N. (2010). Characterization of cyclodextrin inclusion complexes: A review. Journal of Pharmaceutical Science and Technology, 2(3), 171–183.
5. Lala, R., Thorat, A., & Gargote, C. (2011). Current trends in cyclodextrin-based drug delivery system. International Journal of Research in Ayurveda & Pharmacy, 2(5), 1520–1526.
6. Loftsson, T., & Masson, M. (2001). Cyclodextrins in topical drug formulations: Theory and practice. International Journal of Pharmaceutics, 225(1–2), 15–30.
7. Loftsson, T., Brewster, M. E., & Masson, M. (2004). Role of cyclodextrins in improving oral drug delivery. American Journal of Drug Delivery, 2(4), 261–275.
8. Nesna, N., Lou, J., & Breslow, R. (2000). The binding of cocaine to cyclodextrins. Bioorganic & Medicinal Chemistry Letters, 10, 1931–1933.
9. Agarwal, R., & Gupta, V. (2012). Cyclodextrins: A review on pharmaceutical applications for drug delivery. International Journal of Pharmaceutical Research, 2(1), 95–112.
10. Shimpi, S., Chauhan, B., & Shimpi, P. (2005). Cyclodextrins: Application in different routes of drug administration. Acta Pharmaceutica, 55(2), 139–156.
11. Liu, L., & Guo, Q. (2002). The driving forces in the inclusion complexation of cyclodextrins. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 42, 1–14.
12. Singh, R., Bharti, N., Madan, J., & Hiremath, S. N. (2010). Characterization of cyclodextrin inclusion complexes: A review. Journal of Pharmaceutical Science and Technology, 2(3), 171–183.
13. Lala, R., Thorat, A., & Gargote, C. (2011). Current trends in cyclodextrin-based drug delivery system. International Journal of Research in Ayurveda & Pharmacy, 2(5), 1520–1526.
14. Loftsson, T., & Masson, M. (2001). Cyclodextrins in topical drug formulations: Theory and practice. International Journal of Pharmaceutics, 225(1–2), 15–30.
15. Loftsson, T., Brewster, M. E., & Masson, M. (2004). Role of cyclodextrins in improving oral drug delivery. American Journal of Drug Delivery, 2(4), 261–275.